Spark licenses blindness gene therapy rights outside U.S. to Novartis

Updated: Thu, Jan 25, 2018
03:50 am
Reuters
RELATED NEWS
Global growth worry hits stocks, but U.S. data lifts dollar Global growth worry hits stocks, but U.S. data lifts dollar
Oil drops 2 percent on Wall Street losses, weak China data Oil drops 2 percent on Wall Street losses, weak China data
Exclusive: T-Mobile, Sprint parents consider dropping Huawei, see U.S. security clearance for deal - sources Exclusive: T-Mobile, Sprint parents consider dropping Huawei, see U.S. security clearance for deal - sources
China wants to make 'big', 'very comprehensive' deal: Trump China wants to make 'big', 'very comprehensive' deal: Trump
Oil drops 2 percent on Wall St. losses, weak China data Oil drops 2 percent on Wall St. losses, weak China data

Spark Therapeutics Inc , whose breakthrough gene therapy to treat a rare form of blindness was approved by U.S. regulators in December, has licensed rights to the drug in markets outside the United States to Switzerland-based Novartis AG , it said on Wednesday.

Philadelphia-based Spark said it will keep U.S. rights to Luxturna, or voretigene neparvovec, which is the first approved gene therapy for an inherited disease. It plans to launch the one-time treatment in March, charging an unprecedented $850,000.

Spark will receive $105 million from Novartis and up to $65 million in milestone payments based on near-term European regulatory approval and initial sales in certain markets. Spark is also entitled to future royalties on net sales outside the United States.

In a statement, Spark said the deal leverages Novartis` "large, existing commercial and medical infrastructure in ophthalmology, as well as its commitment to commercializing genetic-based medicines."

Novartis last year won U.S. approval for Kymriah, the first of a new type of potent gene-modifying immunotherapy for leukemia.

Luxturna treats inherited retinal disease caused by defects in a gene known as RPE65, which affects between 1,000 and 2,000 people in the United States. It works by delivering by an eye injection viral vector particles containing a correct copy of the gene to retinal cells, restoring their ability to make a needed enzyme.

(This article has not been edited by Zeebiz editorial team and is auto-generated from an agency feed.)

By continuing to use the site, you agree to the use of cookies. You can find out more by clicking this link

Close